Evaluating Blood Biomarker Tests for Alzheimers Diagnosis in Adults with Cognitive Concerns at Primary Care

What this Trial Is About

This research aims to evaluate how blood biomarker tests, specifically ptau217 and the ptau217A42 ratio, performed in primary care affect the care path of individuals with cognitive concerns aged 55 to 85. The study focuses on patients who consult their primary care provider due to worries about their cognitive health, investigating the usefulness of these blood tests in diagnosing Alzheimers Disease at an early stage. All participants will provide a blood sample to measure ptau217 levels as part of the diagnostic evaluation. This is a single-group study where every participant undergoes the same biomarker testing without comparison groups. The study timeline extends over several years, with outcomes assessed at 2 and 4 years to observe changes in referral decisions, diagnoses, and cognitive decline. Participants will be involved through blood sample collection and clinical assessments during their diagnostic workup. Researchers will monitor how biomarker results influence medical decisions and track cognitive changes over time. The primary outcomes include the impact on referral and working diagnosis at 2 years and cognitive decline at 4 years. The study will continue through follow-up assessments lasting up to 4 years to gather these outcome measures.

Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.